These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30765125)

  • 1. Direct-acting antiviral treatment for hepatitis C.
    Holmes JA; Rutledge SM; Chung RT
    Lancet; 2019 Apr; 393(10179):1392-1394. PubMed ID: 30765125
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral drugs have made hepatitis C eminently treatable.
    Ladika S
    Manag Care; 2018 Nov; 27(11):23-30. PubMed ID: 30620304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Selection of direct-acting antiviral agents for chronic hepatitis C infection].
    He YJ; Liu ZH; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):169-172. PubMed ID: 29804388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concerns About Direct-Acting Antiviral Agents for Hepatitis C-Cause for Reassurance.
    Beste LA
    JAMA Netw Open; 2019 Jun; 2(6):e194757. PubMed ID: 31173111
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.
    Maan R; Feld JJ; Duarte-Rojo A
    Aliment Pharmacol Ther; 2017 Aug; 46(3):379-380. PubMed ID: 28677289
    [No Abstract]   [Full Text] [Related]  

  • 7. New Direct-Acting Antiviral Agents Can Be Hepatotoxic in Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis.
    Ou P; Li F; Chen J
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1669-1671. PubMed ID: 27329403
    [No Abstract]   [Full Text] [Related]  

  • 8. Societal Perspectives and Patient/Public Involvement in Direct-Acting Antiviral Agent Coverage of Hepatitis C Treatment in the United States.
    Liu X; Lee JL; Yoo JW
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1814-1815. PubMed ID: 28606844
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C reinfection in prisons with broad access to Direct Acting Antiviral treatments.
    Blogg J; Wright T; McGrath C; Clegg J
    Int J Drug Policy; 2020 Mar; 77():102597. PubMed ID: 31952886
    [No Abstract]   [Full Text] [Related]  

  • 10. The Promise of Direct-Acting Antiviral Therapies to Improve Care and Outcomes in Patients With Cancer Who Have Chronic Hepatitis C Infection.
    Koullias Y; Hammond SP
    J Oncol Pract; 2019 Dec; 15(12):639-640. PubMed ID: 31825757
    [No Abstract]   [Full Text] [Related]  

  • 11. [Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C].
    Research Group for New Drug's Clinical Evalutaion of Critical Diseases and Platform Construction of Integrated Technology
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):161-4. PubMed ID: 27095756
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: hepatitis C direct acting anti-viral agents and the kidney.
    Hussaini T; Yoshida EM
    Aliment Pharmacol Ther; 2017 Aug; 46(3):378-379. PubMed ID: 28677286
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.
    Ohashi H; Koizumi Y; Fukano K; Wakita T; Perelson AS; Iwami S; Watashi K
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):E4527-E4529. PubMed ID: 28512226
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct-acting antiviral therapy for hepatitis E virus?
    Kamar N; Wang W; Dalton HR; Pan Q
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):154-155. PubMed ID: 28404127
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-atherosclerotic cardiac manifestations of chronic hepatitis C virus infection in the era of direct-acting antiviral agents.
    Karimi-Sari H; Rezaee-Zavareh MS
    Atherosclerosis; 2020 Apr; 298():70. PubMed ID: 32147149
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct-acting antiviral regimens matter?
    Ji F; Yeo YH; Wei MT; Wei B; Dang S; Li Z; Nguyen MH
    Hepatology; 2018 Mar; 67(3):1180-1182. PubMed ID: 29194694
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
    Thibault V
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):145-147. PubMed ID: 29371018
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations?
    Ferenci P
    Aliment Pharmacol Ther; 2018 Mar; 47(6):848-849. PubMed ID: 29446143
    [No Abstract]   [Full Text] [Related]  

  • 19. General practitioners require more support to prescribe direct acting antiviral therapy for hepatitis C.
    Sud R; Tiwari N; Forner P; Dowdell L; Freiman J; Zekry A
    Intern Med J; 2018 Jan; 48(1):105-106. PubMed ID: 29314510
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to Retreatment of hepatitis C virus Patients in whom Direct-Acting Antivirals have Failed.
    López Zúñiga MÁ; Prieto Moreno M; de Jesús S; López Ruz MÁ
    Gastroenterol Hepatol; 2019 Nov; 42(9):558-561. PubMed ID: 31320125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.